within Pharmacolibrary.Drugs.ATC.N;

model N05CJ01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 0.017166666666666667,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0492,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010516666666666667,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Suvorexant is an orally active dual orexin receptor antagonist used for the treatment of insomnia. It is approved by the FDA and other regulatory agencies for adult patients who have difficulties with sleep onset and/or sleep maintenance.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose under fasted conditions.</p><h4>References</h4><ol><li>Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata,Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.,Neuropsychopharmacology reports,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34553844/'>https://pubmed.ncbi.nlm.nih.gov/34553844/</a></li><li>Laura H Jacobson, Gabrielle E Callander, Daniel Hoyer,Suvorexant for the treatment of insomnia.,Expert review of clinical pharmacology,2014<a href='https://pubmed.ncbi.nlm.nih.gov/25318834/'>https://pubmed.ncbi.nlm.nih.gov/25318834/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CJ01;
